1. Key Insights
2. Report Introduction
3. Chronic Lower Back Pain Market Overview at a Glance
3.1. Market Share (%) of Chronic Lower Back Pain by Therapies in 2019
3.2. Market Share (%) of Chronic Lower Back Pain by Therapies in 2032
4. Executive Summary of Chronic lower back pain (CLBP)
5. Key Events
6. Chronic Lower Back Pain (CLBP): Disease Background and Overview
6.1. Introduction
6.2. Signs and Symptoms
6.3. Causes and Risk Factors
6.4. Genetics of Chronic Lower Back Pain
6.5. Pathophysiology
6.6. Types of pain
6.7. Diagnosis
6.7.1. Test for CLAB diagnosis
6.7.2. Imaging guidelines
6.8. Treatment and Management
6.8.1. Treatment Approaches
6.8.2. Treatment Algorithm
6.8.3. Proposed Guidelines for Chronic Lower Back Pain
6.8.3.1. NICE Guidelines
6.8.3.2. Center for Disease Control and Prevention (CDC) Guidelines
6.8.3.3. American College of Physicians (ACP) Guidelines
7. Epidemiology and Patient Population
7.1. Key Findings
7.2. Methodology
7.3. Total Prevalent Cases of Chronic Lower Back Pain in the 7MM
7.4. Diagnosed Prevalent Cases of Chronic Lower Back Pain in the 7MM
7.5. The United States
7.5.1. Assumptions and Rationale
7.5.2. Total Prevalent Population of Chronic Lower Back Pain in the United States
7.5.3. Total Diagnosed Prevalent Population of Chronic Lower Back Pain in the United States
7.5.4. Gender-specific Diagnosed Prevalence of Chronic Lower Back Pain in the United States
7.5.5. Age-specific Diagnosed Prevalence of Chronic Lower Back Pain in the United States
7.6. EU5
7.6.1. Assumptions and Rationale
7.6.2. Total Prevalent Population of Chronic Lower Back Pain in EU-5
7.6.3. Total Diagnosed Prevalent Population of Chronic Lower Back Pain in EU-5
7.6.4. Gender-specific Diagnosed Prevalence of Chronic Lower Back Pain in EU-5
7.6.5. Age-specific Diagnosed Prevalence of Chronic Lower Back Pain in EU-5
7.7. Japan
7.7.1. Assumptions and Rationale
7.7.2. Total Prevalent Population of Chronic Lower Back Pain in Japan
7.7.3. Total Diagnosed Prevalent Population of Chronic Lower Back Pain in Japan
7.7.4. Gender-specific Diagnosed Prevalence of Chronic Lower Back Pain in Japan
7.7.5. Age-specific Diagnosed Prevalence of Chronic Lower Back Pain in Japan
8. Patient Journey
9. CLBP Marketed Therapies
9.1. Key Cross Competition
9.2. Cymbalta (Duloxetine): Eli Lilly and Company
9.2.1. Product Description
9.2.2. Regulatory Milestones
9.2.3. Other Developmental Activities
9.2.4. Clinical development
9.2.5. Clinical Trials Information
9.2.6. Safety and Efficacy
9.2.7. Product Profile
9.3. Xtampza: Collegium Pharmaceutical
9.3.1. Product Description
9.3.2. Regulatory Milestones
9.3.3. Other Developmental Activities
9.3.4. Clinical Development
9.3.5. Clinical trial information
9.3.6. Safety and Efficacy
9.3.7. Product Profile
9.4. Hysingla ER: Purdue Pharma LP
9.4.1. Product Description
9.4.2. Regulatory Milestones
9.4.3. Other Developmental Activities
9.4.4. Clinical Development
9.4.5. Clinical trial information
9.4.6. Safety and Efficacy
9.4.7. Product Profile
9.5. Butrans (buprenorphine): Purdue Pharma
9.5.1. Product Description
9.5.2. Regulatory Milestones
9.5.3. Clinical Development
9.5.4. Clinical Trials Information
9.5.5. Safety and Efficacy
9.5.6. Product Profile
9.6. Belbuca: BioDelivery Sciences International
9.6.1. Product Description
9.6.2. Regulatory Milestones
9.6.3. Other Developmental activities
9.6.4. Clinical Development
9.6.5. Clinical Trials Information
9.6.6. Safety and Efficacy
9.6.7. Product Profile
10. Emerging Therapies
10.1. Key Cross Competition
10.2. Brixadi/Buvidal (CAM2038/Buprenorphine Injection Depot): Camurus/Braeburn Inc.
10.2.1. Drug Description
10.2.2. Other Developmental Activities
10.2.3. Clinical Development
10.2.4. Clinical Trials Information
10.2.5. Safety and Efficacy
10.2.6. Product Profile
10.2.7. Analysts’ Views
10.3. Semdexa (SP-102): Scilex Holding
10.3.1. Product Description
10.3.2. Other Developmental Activities
10.3.3. Clinical Development
10.3.4. Clinical Trials Information
10.3.5. Safety and Efficacy
10.3.6. Product Profile
10.3.7. Analysts’ Views
10.4. Rexlemestrocel-L (MPC-06-ID): Mesoblast Limited
10.4.1. Drug Description
10.4.2. Other Developmental Activities
10.4.3. Clinical Development
10.4.4. Clinical Trials Information
10.4.5. Safety and Efficacy
10.4.6. Product Profile
10.4.7. Analysts’ Views
10.5. AMG0103: AnGes MG, Inc.
10.5.1. Drug Description
10.5.2. Clinical Development
10.5.3. Clinical Trials Information
10.5.4. Safety and Efficacy
10.5.5. Product Profile
10.5.6. Analysts’ Views
10.6. KLS-2031: Kolon Life Science
10.6.1. Drug Description
10.6.2. Other Developmental Activities
10.6.3. Clinical Development
10.6.4. Clinical Trials Information
10.6.5. Product Profile
10.6.6. Analysts’ Views
10.7. ETX-810: Eliem Therapeutics
10.7.1. Drug Description
10.7.2. Other Developmental Activities
10.7.3. Clinical Development
10.7.4. Clinical Trials Information
10.7.5. Product Profile
10.7.6. Analysts’ Views
10.8. ALLOD-2: Allodynic Therapeutics
10.8.1. Product Description
10.8.2. Other Developmental Activities
10.8.3. Clinical Development
10.8.4. Clinical Trials Information
10.8.5. Product Profile
10.9. FB3001: Frontier Biotechnologies
10.9.1. Drug Description
10.9.2. Other Developmental Activities
10.9.3. Clinical Development
10.9.4. Clinical Trial Information
10.9.5. Safety and efficacy
10.9.6. Product profile
10.10. IDCT (rebonuputemcel): DiscGenics Inc.
10.10.1. Drug Description
10.10.2. Other Developmental Activities
10.10.3. Clinical Developmental Activities
10.10.4. Clinical trial information
10.10.5. Safety and efficacy
10.10.6. Product Profile
10.10.7. Analysts’ Views
10.11. SX600: SpineThera
10.11.1. Product Description
10.11.2. Other Developmental Activities
10.11.3. Clinical Development
10.11.4. Clinical Trials Information
10.11.5. Product Profile
10.12. STA363: Stayble Therapeutics
10.12.1. Product Description
10.12.2. Other Developmental Activities
10.12.3. Clinical Development
10.12.4. Clinical Trials Information
10.12.5. Product Profile
10.13. Clonidine Micropellets (STX-015): Sollis Therapeutics/Medtronic Spinal and Biologics
10.13.1. Product Description
10.13.2. Other Development Activities
10.13.3. Clinical development
10.13.4. Clinical Trials Information
10.13.5. Safety and Efficacy
10.13.6. Product Profile
10.14. Tanezumab: Eli Lilly/Pfizer
10.14.1. Product Description
10.14.2. Other Developmental Activities
10.14.3. Clinical Development
10.14.4. Clinical Trials Information
10.14.5. Safety and Efficacy
10.14.6. Product Profile
10.14.7. Analysts’ Views
10.15. LY3556050: Eli Lilly and Company
10.15.1. Drug Description
10.15.2. Clinical Development
10.15.3. Clinical Trials Information
10.15.4. Product Profile
10.16. PP353: Persica Pharmaceuticals
10.16.1. Drug Description
10.16.2. Other Developmental Activities
10.16.3. Clinical Development
10.16.4. Clinical Trials Information
10.16.5. Product Profile
10.17. BRTX-100: BioRestorative Therapies
10.17.1. Drug Description
10.17.2. Other Developmental Activities
10.17.3. Clinical Development
10.17.4. Clinical Trials Information
10.17.5. Product Profile
10.17.6. Analysts’ Views
10.18. VER-01: Vertanical GmbH
10.18.1. Drug Description
10.18.2. Clinical Development
10.18.3. Clinical Trials Information
10.18.4. Product Profile
10.19. BM-MSC/ReSpine: Montpellier University Hospital
10.19.1. Product Description
10.19.2. Clinical development
10.19.3. Clinical Trials Information
10.19.4. Product Profile
11. Failed therapies
11.1. Fasinumab (REGN475): Regeneron Pharmaceuticals/Teva Pharmaceuticals
11.1.1. Product Description
11.1.2. Other Developmental Activities
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Product Profile
12. Chronic Lower Back Pain: Seven Major Market Analysis
12.1. Key Findings
12.2. Market Methodology
12.3. CLBP Market Outlook
12.3.1. United States
12.3.2. EU-5 countries
12.3.3. Japan CLBP Market
12.4. Attribute Analysis
12.5. Potential of Emerging Therapies of Chronic Low Back Pain
12.6. Key Market Forecast Assumptions
12.7. Market size of Chronic Lower Back Pain in the 7MM
12.8. Market size of Chronic Lower Back Pain by Therapies in the 7MM
12.9. Market size of Chronic Lower Back Pain in the United States
12.9.1. Total Market size of Chronic Lower Back Pain in the United States
12.9.2. Market Size by Therapies in the US
12.10. Market size of Chronic Lower Back Pain in EU-5
12.10.1. Total Market size of Chronic Lower Back Pain in EU5
12.10.2. Market Size of Chronic Lower Back Pain in EU5 by Therapies
12.11. Market size of Chronic Lower Back Pain in Japan
12.11.1. Total Market size of Chronic Lower Back Pain
12.11.2. Market Size by Therapies in Japan
13. KOL Views
14. CLBP Market Drivers
15. CLBP Market Barriers
16. SWOT Analysis
17. Unmet Needs
18. CLBP Market Access and Reimbursement
19. Appendix
19.1. Report Methodology
19.2. Bibliography
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight
List of Table
Table 1: Summary of CLBP Market and Epidemiology (2019–2032)
Table 2: Key Events
Table 3: Risk Factors for Occurrence and Chronicity of Low Back Pain
Table 4: Cause of Muscle Connective Tissue Fibrosis
Table 5: Clinical Evaluation
Table 6: Graded Chronic Pain Scale (GCPS)
Table 7: Summary of the Efficacy of Physical Treatments for Chronic LBP
Table 8: The American College of Physicians Guideline Grading System
Table 9: Clinical Practice Guideline From the American College of Physicians
Table 10: Total Prevalent Cases of Chronic Lower Back Pain in the 7MM (2019–2032)
Table 11: Diagnosed Prevalent Cases of Chronic Lower Back Pain in the 7MM (2019–2032)
Table 12: Total Prevalent Population of Chronic Lower Back Pain in the United States (2019–2032)
Table 13: Total Diagnosed Prevalent Population of Chronic Lower Back Pain in the United States (2019–2032)
Table 14: Gender-specific Diagnosed Prevalence of Chronic Lower Back Pain in the United States (2019–2032)
Table 15: Age-specific Diagnosed Prevalence of Chronic Lower Back Pain in the US (2019–2032)
Table 16: Total Prevalent Population of Chronic Lower Back Pain in EU-5 (2019–2032)
Table 17: Total Diagnosed Prevalent Population of Chronic Lower Back Pain in EU-5 (2019–2032)
Table 18: Gender-specific Diagnosed Prevalence of Chronic Lower Back Pain in EU-5 (2019–2032)
Table 19: Age-specific Diagnosed Prevalence of Chronic Lower Back Pain in EU5 (2019–2032)
Table 20: Total Prevalent Population of Chronic Lower Back Pain in Japan (2019–2032)
Table 21: Total Diagnosed Prevalent Population of Chronic Lower Back Pain in Japan (2019–2032)
Table 22: Gender-specific Diagnosed Prevalence of Chronic Lower Back Pain in Japan (2019–2032)
Table 23: Age-specific Diagnosed Prevalence of Chronic Lower Back Pain in Japan (2019–2032)
Table 24: Key Cross of Approved Drugs
Table 25: Cymbalta, Clinical Trial Description, 2021
Table 26: Xtampza ER, Clinical Trial Description, 2021
Table 27: Hysingla ER, Clinical Trial Description, 2021
Table 28: Butrans, Clinical Trial Description, 2021
Table 29: Belbuca, Clinical Trial Description, 2021
Table 30: Comparison of emerging drugs under development
Table 31: Brixadi/Buvidal (CAM2038/Buprenorphine Injection Depot), Clinical Trial Description, 2021
Table 32: Semdexa (SP-102), Clinical Trial Description, 2021
Table 33: Rexlemestrocel-L, Clinical Trial Description, 2021
Table 34: AMG0103, Clinical Trial Description, 2021
Table 35: KLS-2031, Clinical Trial Description, 2021
Table 36: ETX-810, Clinical Trial Description, 2021
Table 37: ALLOD-2, Clinical Trial Description, 2021
Table 38: FB3001, Clinical Trial Description, 2021
Table 39: IDCT, Clinical Trial Description, 2021
Table 40: SX600, Clinical Trial Description, 2021
Table 41: STA363, Clinical Trial Description, 2021
Table 42: Clonidine Micropellets, Clinical Trial Description, 2021
Table 43: Tanezumab, Clinical Trial Description 2021
Table 44: LY3556050 Clinical Trial Description, 2021
Table 45: PP353 Clinical Trial Description, 2021
Table 46: BRTX-100, Clinical Trial Description, 2021
Table 47: VER-01, Clinical Trial Description, 2021
Table 48: BM-MSC, Clinical Trial Description, 2021
Table 49: Fasinumab, Clinical Trial Description, 2021
Table 50: Key Market Forecast Assumptions for Brixadi
Table 51: Key Market Forecast Assumptions for Rexlemestrocel-L
Table 52: Key Market Forecast Assumptions for SEMDEXA/SP-102
Table 53: Key Market Forecast Assumptions for Clonidine Micropellets (STX-015)
Table 54: Key Market Forecast Assumptions for Tanezumab
Table 55: Seven Major Market Size of Chronic Lower Back Pain in USD Million (2019–2032)
Table 56: Market Size of Chronic Low Back Pain by therapies in the 7MM, in USD Million (2019–2032)
Table 57: United States Market Size of Chronic Lower Back Pain in USD Million (2019–2032)
Table 58: Market Size of Chronic Low Back Pain by therapies in the US in USD Million (2019–2032)
Table 59: EU-5 Market Size of Chronic Lower Back Pain in USD Million (2019–2032)
Table 60: Market Size of Chronic Low Back Pain by therapies in EU-5 in USD Million (2019–2032)
Table 61: Market Size of Chronic Lower Back Pain in Japan, in USD Million (2019–2032)
Table 62: Market Size of Chronic Low Back Pain by therapies in Japan in USD Million (2019–2032)
List of Figures
Figure 1: Types of Lower Back Pain
Figure 2: Definitions of Chronic Lower Back Pain
Figure 3: Signs and Symptoms of CLBP
Figure 4: Pathophysiological Model for Chronic Low Back Pain Linking Somatic and Behavioral Components
Figure 5: Relationship Describing Therapeutic Inventions and Pathogenic Mechanism
Figure 6: Types of Pain Involved in CLBP mechanism
Figure 7: The Vicious Circle showing the Interaction Of Influencing Factors
Figure 8: Treatment Algorithm for Chronic Low Back Pain
Figure 9: Total Prevalent Cases of Chronic Lower Back Pain in the 7MM (2019–2032)
Figure 10: Diagnosed Prevalent Cases of Chronic Lower Back Pain in the 7MM (2019–2032)
Figure 11: Total Prevalent Population of Chronic Lower Back Pain in the United States (2019–2032)
Figure 12: Total Diagnosed Prevalent Population of Chronic Lower Back Pain in the United States (2019–2032)
Figure 13: Gender-specific Diagnosed Prevalence of Chronic Lower Back Pain in the United States (2019–2032)
Figure 14: Age-specific Diagnosed Prevalence of Chronic Lower Back Pain in the US (2019–2032)
Figure 15: Total Prevalent Population of Chronic Lower Back Pain in EU-5 (2019–2032)
Figure 16: Total Diagnosed Prevalent Population of CLBP in EU-5 (2019–2032)
Figure 17: Gender-specific Diagnosed Prevalence of Chronic Lower Back Pain in EU-5 (2019–2032)
Figure 18: Age - Specific Diagnosed Prevalence of Chronic Lower Back Pain in EU-5 (2019–2032)
Figure 19: Total Prevalent Population of Chronic Lower Back Pain in Japan (2019–2032)
Figure 20: Total Diagnosed Prevalent Population of Chronic Lower Back Pain in Japan (2019–2032)
Figure 21: Gender-specific Diagnosed Prevalence of Chronic Lower Back Pain in Japan (2019–2032)
Figure 22: Age-specific Diagnosed Prevalence of Chronic Lower Back Pain in Japan (2019–2032)
Figure 23: Market Size of Chronic Lower Back Pain in the 7MM, USD Millions (2019–2032)
Figure 24: Market Size of Chronic Lower Back Pain by Therapies in the 7MM, USD Millions (2019–2032)
Figure 25: Market Size of Chronic Lower Back Pain in the United States, USD Millions (2019–2032)
Figure 26: Market size of CLBP by therapies in the United States, in USD Million (2019–2032)
Figure 27: Total Market Size of Chronic Lower Back Pain in EU5, USD Millions (2019–2032)
Figure 28: Market Size of Chronic Low Back Pain by therapies in EU-5, in USD Million (2019–2032)
Figure 29: Market Size of Chronic Lower Back Pain in Japan, USD Millions (2019–2032)
Figure 30: Market Size of Chronic Low Back Pain by therapies in Japan, in USD Million (2019–2032)
Figure 31: Market Drivers
Figure 32: Market Barriers
Figure 33: Unmet Needs
Figure 34: SWOT Analysis